Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Heidelberg – page 22

737 clinical trials in Heidelberg, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Heidelberg at a glance
737
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

737 trials in Heidelberg

Open in trial search

Non-small cell lung cancer

Recruiting

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Non-small cell lung cancer+2

Recruiting

Study on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Universitaetsklinikum Essen AöR

Cardiac failure

Recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Glomerulonephritis minimal lesion+3

Recruiting

Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Sparsentan
  • Sponsor:Travere Therapeutics Inc.

Non-small cell lung cancer

Recruiting

Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for Patients with RAS-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Hypertrophic cardiomyopathy

Recruiting

Study on the Long-Term Safety of Aficamten (CK-3773274) for Patients with Symptomatic Hypertrophic Cardiomyopathy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Cytokinetics Inc.

Plasma cell myeloma

Recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Herpes simplex+1

Recruiting

Study on the Effect of Acyclovir in ICU Patients with Pneumonia and Herpes Simplex Virus Type 1 Detected in Lung Fluid

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Tuberous sclerosis complex

Recruiting

Study on the Effects of Sirolimus and Drug Combination for Children Under 4 Months with Tuberous Sclerosis Complex

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carbamazepine
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Small cell lung cancer+1

Recruiting

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bi 764532
  • Sponsor:Boehringer Ingelheim International GmbH

Pulmonary arterial hypertension

Recruiting

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Heidelberg

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials focusing on heart failure prevention and treatment of TTR amyloidosis cardiovascular complications. Studies evaluating new therapeutic approaches for pulmonary hypertension.

  • Heart Disease Prevention
  • Cardiovascular Safety Studies
  • Amyloidosis Treatment

Research includes evaluation of novel compounds for heart conditions and preventive therapies.

02 Oncology Studies

Comprehensive research in lung cancer, bladder cancer, and melanoma treatments. Advanced trials for various lymphomas and leukemias using innovative therapeutic approaches.

  • Non-Small Cell Lung Cancer
  • Hematological Malignancies
  • Immunotherapy Combinations

Focus on targeted therapies and immunological approaches in cancer treatment.

03 Transplant Medicine

Groundbreaking research in kidney transplantation with innovative immune system modification approaches. Studies exploring new methods to improve transplant outcomes.

  • Living Donor Procedures
  • Immune System Modulation
  • Post-Transplant Care

Emphasis on developing personalized immunosuppression strategies.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.